Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas E Faries

Showing results (11-20 of 75) with videos related to

Pageof 8
Sort By:
Current Medical Research and Opinion|April 10, 2008
Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophreniaDouglas E Faries, Haya Ascher-Svanum, Allen W Nyhuis, et al.
Journal of Medical Economics|February 22, 2013
Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetineZhanglin Cui, Douglas E Faries, Wei Shen, et al.
BMC Psychiatry|September 4, 2009
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophreniaDouglas E Faries, Haya Ascher-Svanum, Allen W Nyhuis, et al.
BMC Family Practice|October 17, 2012
A cross-validation of the provisional diagnostic instrument (PDI-4)Douglas E Faries, John P Houston, Ellen M Sulcs, et al.
Clinical Therapeutics|October 25, 2011
Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspectiveXianchen Liu, Zhanglin Cui, Liyuan Niu, et al.
BMC Research Notes|January 14, 2009
Medication adherence levels and differential use of mental-health services in the treatment of schizophreniaHaya Ascher-Svanum, Baojin Zhu, Douglas E Faries, et al.
Journal of Biopharmaceutical Statistics|April 22, 2025
Double machine learning methods for estimating average treatment effects: a comparative studyXiaoqing Tan, Shu Yang, Wenyu Ye, et al.
Pharmacoepidemiology and Drug Safety|July 12, 2016
"A Bayesian sensitivity analysis to evaluate the impact of unmeasured confounding with external data: a real world comparative effectiveness study in osteoporosis"Xiang Zhang, Douglas E Faries, Natalie Boytsov, et al.
Pharmacoepidemiology and Drug Safety|February 1, 2018
Addressing unmeasured confounding in comparative observational researchXiang Zhang, Douglas E Faries, Hu Li, et al.
BMC Psychiatry|August 30, 2011
Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational studyGebra B Cuyún Carter, Denái R Milton, Haya Ascher-Svanum, et al.
Pageof 8

Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
Current Medical Research and Opinion|April 10, 2008
Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophreniaDouglas E Faries, Haya Ascher-Svanum, Allen W Nyhuis, et al.
Journal of Medical Economics|February 22, 2013
Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetineZhanglin Cui, Douglas E Faries, Wei Shen, et al.
BMC Psychiatry|September 4, 2009
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophreniaDouglas E Faries, Haya Ascher-Svanum, Allen W Nyhuis, et al.
BMC Family Practice|October 17, 2012
A cross-validation of the provisional diagnostic instrument (PDI-4)Douglas E Faries, John P Houston, Ellen M Sulcs, et al.
Clinical Therapeutics|October 25, 2011
Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspectiveXianchen Liu, Zhanglin Cui, Liyuan Niu, et al.
BMC Research Notes|January 14, 2009
Medication adherence levels and differential use of mental-health services in the treatment of schizophreniaHaya Ascher-Svanum, Baojin Zhu, Douglas E Faries, et al.
Journal of Biopharmaceutical Statistics|April 22, 2025
Double machine learning methods for estimating average treatment effects: a comparative studyXiaoqing Tan, Shu Yang, Wenyu Ye, et al.
Pharmacoepidemiology and Drug Safety|July 12, 2016
"A Bayesian sensitivity analysis to evaluate the impact of unmeasured confounding with external data: a real world comparative effectiveness study in osteoporosis"Xiang Zhang, Douglas E Faries, Natalie Boytsov, et al.
Pharmacoepidemiology and Drug Safety|February 1, 2018
Addressing unmeasured confounding in comparative observational researchXiang Zhang, Douglas E Faries, Hu Li, et al.
BMC Psychiatry|August 30, 2011
Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational studyGebra B Cuyún Carter, Denái R Milton, Haya Ascher-Svanum, et al.
Pageof 8